Evidence map›Paper›PMID 37568747›Full record

ArticleCancers2023

Alberta Childhood Cancer Survivorship Research Program.

Andrew Harper, Fiona Schulte, Gregory M T Guilcher, Tony H Truong, Kathleen Reynolds, Maria Spavor, Natalie Logie, Joon Lee, Miranda M Fidler-Benaoudia

Erratum issuedAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Andrew HarperDepartment of Cancer Epidemiology and Prevention Research, Cancer Care Alberta, Alberta Health Services, Calgary, AB T2S 3C3, Canada.
Fiona SchulteDepartment of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.ORCID 0000-0002-3076-9676
Gregory M T GuilcherDepartment of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
Tony H TruongDepartment of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
Kathleen ReynoldsLong Term Survivor's Clinic, Alberta Children's Hospital, Calgary, AB T2N 4N1, Canada.
Maria SpavorDepartment of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2R7, Canada.
Natalie LogieDivision of Radiation Oncology, Tom Baker Cancer Centre, Alberta Health Services, Calgary, AB T2N 4N2, Canada.
Joon LeeData Intelligence for Health Lab, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.ORCID 0000-0001-8593-9321
Miranda M Fidler-BenaoudiaDepartment of Cancer Epidemiology and Prevention Research, Cancer Care Alberta, Alberta Health Services, Calgary, AB T2S 3C3, Canada.ORCID 0000-0001-9594-9881

Funding

Alberta Children's Hospital Foundation CHW 2022University of Calgary CHW 2022
6 · The paper itself

Abstract

Adverse outcomes after childhood cancer have been assessed in a range of settings, but most existing studies are historical and ascertain outcomes only after 5-year survival. Here, we describe the Alberta Childhood Cancer Survivorship Research Program and its foundational retrospective, population-based cohort of Albertan residents diagnosed with a first primary neoplasm between the ages of 0 and 17 years from 1 January 2001 to 31 December 2018. The cohort was established in collaboration with the Alberta Cancer Registry and Cancer in Young People in Canada program and has been linked to existing administrative health databases and patient-reported outcome questionnaires. The cohort comprised 2581 survivors of childhood cancer, 1385 (53.7%) of whom were 5-year survivors. Approximately 48% of the cohort was female, 46% of the cohort was diagnosed between 0 and 4 years of age, and the most frequent diagnoses were leukemias (25.3%), central nervous system tumors (24.2%), and lymphomas (14.9%). Detailed treatment information was available for 1745 survivors (67.6%), with manual abstraction ongoing for those with missing data. By the study exit date, the median time since diagnosis was 5.6 years overall and 10.3 years for 5-year survivors. During the follow-up time, 94 subsequent primary cancers were diagnosed, 16,669 inpatient and 445,150 ambulatory/outpatient events occurred, 396,074 claims were reported, and 408 survivors died. The results from this research program seek to inform and improve clinical care and reduce cancer-related sequelae via tertiary prevention strategies.

Indexed as

childhood cancerepidemiologypediatric cancersurvivorship

Identifiers

PMID37568747
PMCPMC10417797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.